Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Ramucirumab + Erlotinib for Lung Cancer
Recruiting1 awardPhase 3
Edmonton, Alberta
This trial is evaluating the efficacy and safety of ramucirumab in combination with erlotinib or gefitinib as compared to placebo in previously untreated participants with stage IV non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.